Cocrystal Pharma, Inc. COCP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-115.15
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$8.8M | — | -$8.2M | $6.3M |
| 2024 | — | -$17.5M | — | -$16.5M | $9.5M |
| 2023 | — | -$18.0M | — | -$14.8M | $26.4M |
| 2022 | — | -$38.8M | — | -$21.5M | $39.6M |
| 2021 | — | -$14.2M | — | -$12.8M | $77.5M |
| 2020 | $2.0M | -$9.6M | — | -$10.1M | $52.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | director | 2026-02-24 | Buy | 20,000 | $1.00 |
| FROST PHILLIP MD ET AL | director | 2026-02-06 | Buy | 50,000 | $0.95 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -115.15 (distress)
- Working capital / assets 0.61
- Retained earnings / assets -35.24
- EBIT / assets -0.929
- Equity / liabilities 1.873
Source: SEC EDGAR filings · CIK 0001412486 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.